S-1/A: Mangoceuticals Files Amendment No. 1 to Form S-1 Registration Statement for Resale of Common Stock

Mangoceuticals is registering shares for resale by selling stockholders, with proceeds to the company from ELOC and warrant exercises used for working capital.

Summary

• Mangoceuticals has filed an amendment to its Form S-1 registration statement to register the resale of up to 30,014,286 shares of its common stock by selling stockholders.
• The company will not receive any proceeds from the sale of these shares by the selling stockholders.
• Proceeds received by the company from the sale of shares pursuant to an Equity Line of Credit (ELOC) and from the exercise of warrants will be used for general working capital.
• The shares being registered include (i) 1,000,000 shares issued as a commitment fee for the ELOC, (ii) 10,000,000 shares issuable under the ELOC at an adjusted price of $0.26 per share, (iii) 3,300,000 shares issuable upon exercise of warrants at $0.26 per share, and (iv) 15,714,286 shares issuable upon conversion of Series B Convertible Preferred Stock at an assumed conversion price of $0.035 per share.
• The company has reserved 50,000,000 shares of common stock for the exercise of warrants and conversion of the Series B Preferred Stock.
• The timing and amount of any sales are at the selling stockholders' sole discretion, subject to certain restrictions.
• Mangoceuticals is an emerging growth company and has elected to comply with certain reduced public company disclosure and reporting requirements.
• The last sale price per share of Mangoceuticals' common stock on May 3, 2024, was $0.264.

Sentiment

Score: 4

Explanation: The document presents a mixed sentiment. While there are positive aspects such as the potential for growth and the company's efforts to expand its operations, there are also significant risks and challenges, including the company's lack of profitability, reliance on related party transactions, and regulatory hurdles. The overall sentiment is cautiously optimistic, but with a clear recognition of the significant challenges ahead.

Positives

• The company will receive proceeds from the ELOC and warrant exercises, which will be used for general working capital.
• The registration allows selling stockholders to sell their shares, potentially increasing liquidity in the market.
• The company is an emerging growth company, allowing for reduced disclosure requirements.

Negatives

• The company will not receive any proceeds from the sale of shares by the selling stockholders.
• The timing and amount of sales are at the selling stockholders' discretion, which could lead to unpredictable market activity.
• The company's stock price is volatile and could decline.
• The company is not profitable and has a limited operating history.

Risks

• The company may not be able to generate revenues or sell any commercial amount of its products in the future.
• The company will need to raise additional funding to support its operations in the future.
• The company faces intense competition from companies with greater resources and experience.
• The company's ED product has not been, and will not be, approved by the FDA and has not had the benefit of the FDAs clinical trial protocol which seeks to prevent the possibility of serious patient injury and death.
• The FDA may determine that the compounding of the company's planned products does not fall within the exemption from the FFDCA Act provided by Section 503A.
• The company has a significant reliance on related party transactions and risks associated with such related party relationships and agreements.
• The company is exposed to risks associated with credit card and other online payment chargebacks and fraud.
• The company may be unable to scale its operations fast enough to bring down its cost of sales and generate revenues sufficient to support its operations.
• The company may not be able to successfully compete with larger competitors that have greater financial, sales, technical and other resources.
• The company's business depends on its brand, and any failure to maintain, protect or enhance its brand, including as a result of events outside its control, could materially adversely affect its business.
• The company's common stock may be delisted from the Nasdaq Capital Market if it fails to comply with the continued minimum closing bid requirements or other requirements for continued listing, and the price of its common stock and its ability to access the capital markets could be negatively impacted.

Future Outlook

The company plans to continue using the same marketing and management strategies and continue providing a quality product with excellent customer service while also seeking to expand its operations organically or through acquisitions as funding and opportunities arise.

Industry Context

The announcement reflects a company in the mens wellness telemedicine sector seeking to raise capital and expand its operations, while navigating regulatory challenges and competition from larger players.

Comparison to Industry Standards

• The document mentions Hims & Hers Health, Inc. and Roman as competitors in the mens wellness space.
• It also identifies Viagra (Pfizer) and Cialis (Lilly ICOS LLC) as competitors for Mango ED, and Propecia (Merck & Co.) and Rogaine (Johnson & Johnson) as competitors for Mango GROW.
• The document references market reports from Verified Market Research and Grand View Research regarding the erectile dysfunction drugs market.
• The document references a market study from The Insight Partners regarding the hair loss prevention products market.

Related Party Transactions

• The company has entered into a Master Services Agreement and Statement of Work with Epiq Scripts, LLC, a related party, 51% owned and controlled by Jacob D. Cohen, the company's Chairman and Chief Executive Officer.
• The company has entered into a Consulting Agreement with Epiq Scripts, LLC, a related party, 51% owned and controlled by Jacob D. Cohen, the company's Chairman and Chief Executive Officer.
• The company has entered into a First Addendum to Master Services Agreement with Epiq Scripts, LLC, a related party, 51% owned and controlled by Jacob D. Cohen, the company's Chairman and Chief Executive Officer.
• The company has entered into a Consulting Agreement with PHX Global, LLC, which is owned by Peter Casey Jensen, who was a member of the Board of Directors of American International.
• The company has entered into a Consulting Agreement with Cohen Enterprises, Inc., which is owned by Jacob D. Cohen, the company's Chairman and Chief Executive Officer.
• The company has entered into a service agreement with Greentree Financial Group, Inc., where Eugene M. Johnston, the company's Chief Financial Officer, serves as Audit Manager.

Stakeholder Impact

• Shareholders may experience dilution from the issuance of additional shares of common stock.
• Shareholders may experience volatility in the market price of the company's common stock.
• The company's ability to attract and retain key personnel may be affected by its financial performance and the terms of its compensation plans.
• Customers may be affected by the company's ability to provide quality products and services and to comply with applicable regulations.

Next Steps

• The selling stockholders may offer and sell shares of common stock from time to time.
• The company may sell shares of common stock pursuant to the ELOC.
• The company may seek additional funding through equity financings, debt financings or other capital sources.

Key Dates

Keywords

common stock, resale, registration statement, ELOC, warrants, Series B Preferred Stock, selling stockholders, Mangoceuticals, MGRX